Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2020

26.06.2020 | Epidemiology

Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management

verfasst von: Marianna Cavazza, Helen Banks, Michele Ercolanoni, Gjiliola Cukaj, Giulia Bianchi, Giuseppe Capri, Francesco Longo

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Adjuvant endocrine therapy (AET) for ≥ 5 years is generally recommended for women with hormone receptor-positive breast cancer to reduce cancer recurrence/mortality; however, adherence can be suboptimal. We tested determinants of AET adherence using patient characteristics, treatment pathways, AET initiation timing, and multiple healthcare facility use. An underlying objective was to explore how oncological pathways mirror chronic disease management to monitor adherence and target improvement interventions using administrative datasets.

Methods

Using patient-linked administrative health data from the Italian Lombardy Region, we identified 33.291 surviving patients starting AET in 2010–2016, with two (22.939 patients) or five years (8400 patients) follow-up, using a ≥ 80% prescription refill approach to measure adherence and logistic regression to test determinants of adherence.

Results

AET crude adherence falls significantly during follow-up, from 94% at 1 Year to 58% at 5 Years. At 5 Years, patients who were older (>70), prescribed tamoxifen-only (OR 0.69; 95% CI 0.57–0.83; p = 0.0001) vs. aromatase inhibitors-only or therapy switches, treated for depression (OR 0.68; 95% CI 0.60–0.78; p < 0.0001), with surgery performed in high-volume hospitals (OR 0.85; 95% CI 0.75–0.97; p = 0.0116) showed lower adherence. Loyalty, or continued care in the surgical hospital (OR 1.73; 95% CI 1.51–2.00; p < 0.0001), undergoing chemotherapy before AET (OR 2.65; 95% CI 2.02–3.48; p < 0.0001), and earlier AET initiation, positively influenced adherence.

Conclusions

Chronic disease monitoring using administrative data can help oncologists focus efforts to ensure AET adherence. Results suggest addressing mental health, age, disease severity patient perceptions, timely AET initiation and therapy switches, and encouraging continued follow-up in the same hospital or better care coordination with outside follow-up specialists.
Literatur
5.
Zurück zum Zitat Tremont A, Lu J, Cole JT (2017) Endocrine therapy for early breast cancer: updated review. Ochsner J 17:405–411PubMedPubMedCentral Tremont A, Lu J, Cole JT (2017) Endocrine therapy for early breast cancer: updated review. Ochsner J 17:405–411PubMedPubMedCentral
24.
28.
Zurück zum Zitat Canfield SL, Zuckerman A, Anguiano RH et al (2019) Navigating the wild west of medication adherence reporting in specialty pharmacy. JMCP 25:1073–1077CrossRefPubMed Canfield SL, Zuckerman A, Anguiano RH et al (2019) Navigating the wild west of medication adherence reporting in specialty pharmacy. JMCP 25:1073–1077CrossRefPubMed
34.
Zurück zum Zitat Ministero della Salute (2015) Decreto Ministeriale 2 aprile 2015 n. 70. Regolamento recante definizione degli standard qualitativi, strutturali, tecnologici e quantitativi relativi all’assistenza ospedaliera. (G.U. 4 giugno 2015, n. 127). Ministero della Salute (2015) Decreto Ministeriale 2 aprile 2015 n. 70. Regolamento recante definizione degli standard qualitativi, strutturali, tecnologici e quantitativi relativi all’assistenza ospedaliera. (G.U. 4 giugno 2015, n. 127).
Metadaten
Titel
Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management
verfasst von
Marianna Cavazza
Helen Banks
Michele Ercolanoni
Gjiliola Cukaj
Giulia Bianchi
Giuseppe Capri
Francesco Longo
Publikationsdatum
26.06.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05748-6

Weitere Artikel der Ausgabe 1/2020

Breast Cancer Research and Treatment 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.